Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas

医学 揭穿 肿瘤科 内科学 浆液性液体 化疗 卵巢癌 浆液性癌 癌症 透明细胞癌 回顾性队列研究 阶段(地层学) 流行病学 监测、流行病学和最终结果 癌症登记处 古生物学 生物
作者
Koji Matsuo,Shinya Matsuzaki,Michihide Maeda,Alesandra R. Rau,Kosuke Yoshihara,Ryo Tamura,Muneaki Shimada,Hiroko Machida,Mikio Mikami,Maximilian Klar,Lynda D. Roman,Jason Dennis Wright,Anil K. Sood,David Marc Gershenson
出处
期刊:JAMA network open [American Medical Association]
卷期号:6 (6): e2318602-e2318602 被引量:24
标识
DOI:10.1001/jamanetworkopen.2023.18602
摘要

Importance: Randomized clinical trials examining the effectiveness of neoadjuvant chemotherapy (NACT) for advanced ovarian cancer predominantly included patients with high-grade serous carcinomas. The use and outcomes of NACT in less common epithelial carcinomas are understudied. Objective: To investigate the uptake and survival outcomes in treatment with NACT for less common histologic subtypes of epithelial ovarian cancer. Design, Setting, and Participants: A retrospective cohort study and systematic literature review with meta-analysis was conducted using the National Cancer Database from 2006 to 2017 and the National Cancer Institute's Surveillance, Epidemiology, and End Results Program from 2006 to 2019. Data analysis was performed from July 2022 to April 2023. The evaluation included patients with stage III to IV ovarian cancer with clear cell, mucinous, or low-grade serous histologic subtypes who received multimodal treatment with surgery and chemotherapy. Exposures: Exposure assignment per the sequence of treatment: primary debulking surgery (PDS) followed by chemotherapy (PDS group) or NACT followed by interval surgery (NACT group). Main Outcomes and Measures: Temporal trends and characteristics of NACT use were assessed using multivariable analysis, and overall survival (OS) was assessed with the inverse probability of treatment weighting propensity score. Results: A total of 3880 patients were examined in the National Cancer Database including 1829 women (median age, 56 [IQR, 49-63] years) with clear cell, 1156 women (median age, 53 [IQR, 42-64] years) with low-grade serous, and 895 women (median age, 57 [IQR, 48-66] years) with mucinous carcinomas. NACT use increased in patients with clear cell (from 10.2% to 16.2%, 58.8% relative increase; P < .001 for trend) or low-grade serous (from 7.7% to 14.2%, 84.4% relative increase; P = .007 for trend) carcinoma during the study period. This association remained consistent in multivariable analysis. NACT use also increased, but nonsignificantly, in mucinous carcinomas (from 8.6% to 13.9%, 61.6% relative increase; P = .07 for trend). Across the 3 histologic subtypes, older age and stage IV disease were independently associated with NACT use. In a propensity score-weighted model, the NACT and PDS groups had comparable OS for clear cell (4-year rates, 31.4% vs 37.7%; hazard ratio [HR], 1.12; 95% CI, 0.95-1.33) and mucinous (27.0% vs 26.7%; HR, 0.90; 95% CI, 0.68-1.19) carcinomas. For patients with low-grade serous carcinoma, NACT was associated with decreased OS compared with PDS (4-year rates, 56.4% vs 81.0%; HR, 2.12; 95% CI, 1.55-2.90). Increasing NACT use and histologic subtype-specific survival association were also found in the Surveillance, Epidemiology, and End Results Program cohort (n = 1447). A meta-analysis of 4 studies, including the current study, observed similar OS associations for clear cell (HR, 1.13; 95% CI, 0.96-1.34; 2 studies), mucinous (HR, 0.93; 95% CI, 0.71-1.21; 2 studies), and low-grade serous (HR, 2.11; 95% CI, 1.63-2.74; 3 studies) carcinomas. Conclusions and Relevance: Despite the lack of data on outcomes of NACT among patients with less common carcinomas, this study noted that NACT use for advanced disease has gradually increased in the US. Primary chemotherapy for advanced-stage, low-grade serous ovarian cancer may be associated with worse survival compared with PDS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
怕孤单的筮完成签到,获得积分10
2秒前
贾春阳完成签到 ,获得积分10
3秒前
3秒前
Linxiang的应助被名古邬采纳,获得20
4秒前
丰收喵完成签到 ,获得积分10
5秒前
冯聪聪发布了新的文献求助10
5秒前
科研通AI6.3的应助被zont1x采纳,获得10
6秒前
秋风的应助被叮咚咚采纳,获得10
6秒前
吴趣发布了新的文献求助10
8秒前
xiaolong发布了新的文献求助10
8秒前
ffcc123完成签到 ,获得积分10
8秒前
张伟的应助被漫漫采纳,获得10
9秒前
9秒前
顾矜的应助被秦白采纳,获得10
9秒前
zilicai的应助被CITY111119采纳,获得10
10秒前
专注的荣轩完成签到,获得积分10
10秒前
人好像不在完成签到,获得积分20
11秒前
Lumos完成签到,获得积分10
11秒前
药镜完成签到,获得积分10
11秒前
13秒前
stc完成签到,获得积分10
13秒前
14秒前
刘玲完成签到 ,获得积分10
14秒前
15秒前
15秒前
拔丝兔子完成签到 ,获得积分10
16秒前
16秒前
jiangjiang完成签到,获得积分10
16秒前
17秒前
17秒前
20秒前
nicholasgxz完成签到,获得积分10
20秒前
鳗鱼安阳完成签到 ,获得积分10
20秒前
大个的应助被lxh采纳,获得10
21秒前
一只鱼完成签到,获得积分10
21秒前
zheng完成签到,获得积分10
22秒前
Pam完成签到,获得积分10
23秒前
Moonds发布了新的文献求助10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181823
求助须知:如何正确求助?哪些是违规求助? 9571511
关于积分的说明 21818391
捐赠科研通 7778076
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479614